Pazopanib combined with doxorubicin and cisplatin in recurrent osteosarcoma: A retrospective cohort study.

Medicine (Baltimore) · 2026 · PMC12794992 · PMID 41517779

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP = .13not close (p > 0.1)

Overall, the ORR in the exposure group was 26.0%, which was higher than that in the control group (14.0%), although the difference did not reach statistical significance ( P = .13).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.